SCHEMBL25657183

SCHEMBL25657183

CCCN(C)C(=O)OCOP(=O)(O)O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 7/20 0.36
LPAR1 Q92633 5/20 0.36
LPAR2 Q9HBW0 3/20 0.36
FDPS P14324 1/20 0.33
ENPP2 Q13822 6/20 0.33
LPAR6 P43657 1/20 0.33
LPAR4 Q99677 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
ACHE P22303 1/20 0.32
MVD P53602 2/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP8 P22894 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25021047 0.85 LPAR3 (0.34) LPAR3LPAR1LPAR2ENPP2LPAR6
SCHEMBL38659094 0.84 TPI1 (0.32) CHRNB2CHRNB4CHRNA3CHRNA4MVD
SCHEMBL25788481 0.81 CHRNB2 (0.40) CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL25019697 0.77 CA12 (0.33) CHRNB2CHRNB4CHRNA3CHRNA4MVD
SCHEMBL38659925 0.77 MVD (0.33) MVD
SCHEMBL254842 0.74 ALDH1A1 (0.42) CHRNB2CHRNB4CHRNA3CHRNA4ACHE
SCHEMBL18125070 0.72 CHRNB2 (0.46) CHRNB2CHRNB4CHRNA3CHRNA4ACHE
Ammonia Solution, Strong SCHEMBL29011843 0.72 ALDH1A1 (0.40) CHRNB2CHRNB4CHRNA3CHRNA4ACHE
SCHEMBL23084692 0.71 CA12 (0.32) MVD
SCHEMBL7360558 0.71 CHRNB2 (0.37) CHRNB2CHRNB4CHRNA3CHRNA4ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230141284-A1 CANCER THERAPEUTIC METHOD ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141284-A1 CANCER THERAPEUTIC METHOD STING1, CGAS, IFNAR1 LPAR3 458/4885LPAR1 220/4885LPAR2 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.